Nitric Oxide and sex differences in cardiac repair
一氧化氮和心脏修复中的性别差异
基本信息
- 批准号:9331951
- 负责人:
- 金额:$ 40.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-17 至 2021-02-28
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAlcohol dehydrogenaseAngiotensin IIAntioxidantsAttentionBuffersCardiacCardiac MyocytesCardiovascular AbnormalitiesCardiovascular DiseasesCardiovascular PhysiologyCardiovascular systemCause of DeathClinicalComplicationCysteineDataDevelopmentDisease OutcomeEnzymesEquilibriumEstrogen ReceptorsExhibitsFemaleGenderGlutathione DisulfideHeartHeart DiseasesHormonalInjuryLeadMediatingMenopauseModelingMusMyocardial InfarctionMyocardial dysfunctionNitric OxideOutcomeOxidation-ReductionOxidative StressOxidoreductasePPAR gammaPathologyPathway interactionsPeroxisome Proliferator-Activated ReceptorsPhenotypePhosphorylationPhysiologicalPlayPre-EclampsiaPregnancyPregnancy ComplicationsPremenopauseProcessProductionProtein SProteinsProteinuriaReactive Oxygen SpeciesRegulationRoleS-NitrosoglutathioneSex CharacteristicsSignal PathwaySignal TransductionSignaling ProteinSiteSourceStressSulfhydryl CompoundsSyndromeSystemTXN geneTestingTherapeuticTreatment EfficacyVascular blood supplyWomanascorbatebasecalmodulin-dependent protein kinase IIcardiac repaircardiovascular healtheffective therapyexperiencegender differenceimprovedinsightmalematernal hypertensionmenmortalitynoveloxidative damagepregnantprogramsprotective effectresponsesexstressor
项目摘要
Project Summary: This program will have a major impact in the treatment of cardiovascular disease (CVD),
the leading cause of death in men and women globally. Premenopausal women are less susceptible to heart
disease than men, and this protection is lost after menopause. Emerging data suggest that the interplay
between nitric oxide (NO) and reactive oxygen species (ROS), the nitroso-redox balance, plays a critical role in
this sex-related cardioprotection. Elucidating the mechanisms underlying these gender differences is critical for
development of effective therapies. S-nitrosylation (S-NO) of cysteine thiols is a major signaling pathway
through which NO exerts its broad regulatory actions. It is increasingly appreciated that the underlying
signaling fate of NO ultimately depends upon an intracellular state of nitroso-redox balance; such that
excessive production of ROS can disrupt physiological S-NO and that CVD may reflect dysregulated protein S-
NO. We have shown that the nitroso/redox balance is an important regulator of CV health and disease. Female
mice have 65% more S-nitrosylated proteins in the heart6 and physiologically regulate this elevated level of S-
NO with increased activity of S-nitrosoglutathione (GSNO) reductase (GSNOR), an enzyme that promotes
protein denitrosylation. We previously showed that male mice lacking S-nitrosoglutathione (GSNO) reductase,
an enzyme that governs S-NO levels by promoting protein denitrosylation (GSNOR−⁄− mice) exhibit improved
survival after myocardial infarction (MI). Furthermore, pregnant GSNOR−/− mice exhibit all of the clinical
features of a major complication in pregnancy, preeclampsia (PE), including maternal hypertension, proteinuria
and abnormal CV adaptation. Poor outcome in the GSNOR−/− females may be due to oxidative stress, as our
preliminary data shows that cardiomyocytes (CMs) from GSNOR−/− females generate more ROS as compared
to CMs from control females and GSNOR−/− males. Therefore, the state of increased S-NO can lead to an
adverse milieu if accompanied by oxidative stress and we have uncovered a sex-associated relationship
between cardiac pathology and intra-cellular nitroso-redox imbalance, which is dependent on NO and ROS
production and S-NO formation and denitrosylation. Our central hypothesis is that the absence of GSNOR
produces a sex-specific, antioxidant milieu in the setting of normal ROS levels (i.e., males) but one of
nitrosative/oxidative stress when ROS is elevated (i.e., females). Our proposal aims to identify the fundamental
mechanisms underlying this dichotomy. The specific aims are to test the hypotheses that 1) differences in
nitroso-redox protein signaling determine sex-specific responses to CV stress; 2) nitroso-redox imbalance in
cadiomyocytes during pregnancy underlies pregnancy-related CVD; and 3) GSNOR produces sex-specific
changes in the S-nitrosylation of proteins that alter CV function. Together these aims will provide novel insights
into nitroso-redox regulation of cardiac function in response to physiologic and pathophysiologic stressors and
have significant implications for the treatment of CVD in men and women.
项目概述:本项目将对心血管疾病(CVD)的治疗产生重大影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joshua M Hare其他文献
Nitrite Mediated Neuroprotection and Signaling after Cardiac Arrest
- DOI:
10.1016/j.freeradbiomed.2010.10.433 - 发表时间:
2010-01-01 - 期刊:
- 影响因子:
- 作者:
Cameron Dezfulian;Aleksey Alekseyenko;Joshua M Hare;Miguel A Perez-Pinzon - 通讯作者:
Miguel A Perez-Pinzon
Joshua M Hare的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joshua M Hare', 18)}}的其他基金
Full-scale GMP Production for a Pre-Clinical Systemic Delivered Mesenchymal Stem Cells Derived Extracellular Vesicles For Cardiovascular Disease
用于治疗心血管疾病的临床前全身输送间充质干细胞衍生的细胞外囊泡的全面 GMP 生产
- 批准号:
10721103 - 财政年份:2023
- 资助金额:
$ 40.61万 - 项目类别:
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial
1/2 异体人间充质干细胞 (MSC) 注射治疗左心发育不全综合征患者:IIb 期临床试验
- 批准号:
10274833 - 财政年份:2020
- 资助金额:
$ 40.61万 - 项目类别:
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial
1/2 异体人间充质干细胞 (MSC) 注射治疗左心发育不全综合征患者:IIb 期临床试验
- 批准号:
10295008 - 财政年份:2020
- 资助金额:
$ 40.61万 - 项目类别:
Production Assistance for Cellular Therapies (PACT)- Cell Processing Facilities Cell manufacturing and process development services for PCT0031-02: GMP Production of iPSC Line and Scale-up of Cardiac
细胞疗法生产协助 (PACT) - 细胞加工设施 PCT0031-02 的细胞制造和工艺开发服务:iPSC 生产线的 GMP 生产和心脏的放大
- 批准号:
10090766 - 财政年份:2019
- 资助金额:
$ 40.61万 - 项目类别:
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty
研究 Longeveron 间充质干细胞 (LMSC) 治疗衰老衰弱功效的 2b 期临床试验
- 批准号:
9922198 - 财政年份:2018
- 资助金额:
$ 40.61万 - 项目类别:
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
一项评估 Longeveron 间充质干细胞 (LMSC) 疗法治疗代谢综合征的随机、盲法、安慰剂对照临床试验
- 批准号:
9925908 - 财政年份:2017
- 资助金额:
$ 40.61万 - 项目类别:
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
一项评估 Longeveron 间充质干细胞 (LMSC) 疗法治疗代谢综合征的随机、盲法、安慰剂对照临床试验
- 批准号:
9348026 - 财政年份:2017
- 资助金额:
$ 40.61万 - 项目类别:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
非缺血性扩张型心肌病的细胞疗法
- 批准号:
8288406 - 财政年份:2012
- 资助金额:
$ 40.61万 - 项目类别:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
非缺血性扩张型心肌病的细胞疗法
- 批准号:
8448599 - 财政年份:2012
- 资助金额:
$ 40.61万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 40.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 40.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 40.61万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 40.61万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 40.61万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 40.61万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 40.61万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 40.61万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 40.61万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 40.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)